

6. Literaturverzeichnis

- (1) Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005; 55(2):74-108.
- (2) Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM. Metastatic and histologic presentations in unknown primary cancer. *Semin Oncol* 1977; 4(1):53-58.
- (3) Schirrmeyer H, Guhlmann A, Kotzerke J, Santjohanser C, Kuhn T, Kreienberg R et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. *J Clin Oncol* 1999; 17(8):2381-2389.
- (4) Moro L, Gazzarrini C, Crivellari D, Galligioni E, Talamini R, de Bernard B. Biochemical markers for detecting bone metastases in patients with breast cancer *Clin Chem* 1993; 39(1):131-134.
- (5) Wada N, Fujisaki M, Ishii S, Ikeda T, Kitajima M. Evaluation of bone metabolic markers in breast cancer with bone metastasis *Breast Cancer* 2001; 8(2):131-137.
- (6) Berruti A, Torta M, Piovesan A, Raucci CA, Orlandi F, Panero A et al. Biochemical picture of bone metabolism in breast cancer patients with bone metastases. *Anticancer Res* 1995; 15(6B):2871-2875.
- (7) Burgeson RE. New collagens, new concepts *Annu Rev Cell Biol* 1988; 4:551-577.
- (8) Lacroix M, Marie PJ, Body JJ. Protein production by osteoblasts: modulation by breast cancer cell-derived factors *Breast Cancer Res Treat* 2000; 61(1):59-67.
- (9) Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen *Clin Chem* 1996; 42(6 Pt 1):947-954.
- (10) Orum O, Hansen M, Jensen CH, Sorensen HA, Jensen LB, Horslev-Petersen K et al. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism *Bone* 1996; 19(2):157-163.
- (11) Price KM, Silman R, Armstrong P, Grudzinskas JG. Development of a radioimmunoassay for fetal antigen 2 *Clin Chim Acta* 1994; 224(1):95-102.
- (12) Elomaa I, Risteli L, Laakso M, Lahtinen R, Virkkunen P, Risteli J. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. *Eur J Cancer* 1996; 32A(7):1166-1170.

- (13) Koizumi M, Yonese J, Fukui I, Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. *BJU Int* 2001; 87(4):348-351.
- (14) Tahtela R, Tholix E. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer
Anticancer Res 1996; 16(4B):2289-2293.
- (15) Saarto T, Blomqvist C, Risteli J, Risteli L, Sarna S, Elomaa I. Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients. *Br J Cancer* 1998; 78(2):240-245.
- (16) Berg RA, Prockop DJ. The thermal transition of a non-hydroxylated form of collagen. Evidence for a role for hydroxyproline in stabilizing the triple-helix of collagen. *Biochem Biophys Res Commun* 1973; 52(1):115-120.
- (17) Brandt J, Krogh TN, Jensen CH, Frederiksen JK, Teisner B. Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology
Clin Chem 1999; 45(1):47-53.
- (18) Jensen CH, Hansen M, Brandt J, Rasmussen HB, Jensen PB, Teisner B. Quantification of the N-terminal propeptide of human procollagen type I (PINP): comparison of ELISA and RIA with respect to different molecular forms
Clin Chim Acta 1998; 269(1):31-41.
- (19) A first technical and clinical review of a new automated serum PINP assay. Nov; 2000.
- (20) Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment
Cancer 1981; 47(1):207-214.
- (21) WHO. WHO handbook for reporting results of cancer treatment. 1979.
- (22) Vesper H, Cosman F, Endres DB, Garnero P, Hoyle NR, Kleerekoper M et al. Application of biochemical markers of bone turnover in the assessment and monitoring of bone diseases; approved guideline C48-A
In: NCCLS, editor. 2004.
- (23) Bon GG, Mensdorff-Pouilly S, Kenemans P, van Kamp GJ, Verstraeten RA, Hilgers J et al. Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. *Clin Chem* 1997; 43(4):585-593.
- (24) Tahtela R, Turpeinen M, Sorva R, Karonen SL. The aminoterminal propeptide of type I procollagen: evaluation of a commercial radioimmunoassay kit and values in healthy subjects. *Clin Biochem* 1997; 30(1):35-40.

- (25) Fay TN, Jacobs I, Teisner B, Poulsen O, Chapman MG, Stabile I et al. Two fetal antigens (FA-1 and FA-2) and endometrial proteins (PP12 and PP14) isolated from amniotic fluid; preliminary observations in fetal and maternal tissues
Eur J Obstet Gynecol Reprod Biol 1988; 29(1):73-85.
- (26) Price KM, Silman R, Armstrong P, Grudzinskas JG. Development of a radioimmunoassay for fetal antigen 2. Clin Chim Acta 1994; 224(1):95-102.
- (27) Rasmussen HB, Teisner B, Bangsgaard-Petersen F Y-AEKM. Quantification of fetal antigen 2 (FA2) in supernatants of cultured osteoblasts, normal human serum and serum from patients with chronic renal failure. Nephrol Dial Transplant 2006;(1992;7:902-907).
- (28) Goldberg B, Taubman MB, Radin A. Procollagen peptidase: its mode of action on the native substrate
Cell 1975; 4(1):45-50.
- (29) Diaz-Martin MA, Traba ML, de la PC, Guerrero R, Mendez-Davila C, De La Pena EG. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma. Scand J Clin Lab Invest 1999; 59(2):125-132.
- (30) Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004; 111(5):783-791.
- (31) de la PC, Castro-Errecaborde NA, Traba ML, Mendez-Davila C, Garcia-Moreno C, Rodriguez dA et al. Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 2003; 331(1-2):45-53.
- (32) Ebert W, Muley T, Herb KP, Schmidt-Gayk H. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients
Anticancer Res 2004; 24(5B):3193-3201.
- (33) Coleman RE, Mashiter G, Fogelman I, Whitaker KD, Caleffi M, Moss DW et al. Osteocalcin: a potential marker of metastatic bone disease and response to treatment.
Eur J Cancer Clin Oncol 1988; 24(7):1211-1217.
- (34) Kamby C, Egsomose C, Soletormos G, Dombernowsky P. The diagnostic and prognostic value of serum bone Gla protein (osteocalcin) in patients with recurrent breast cancer. Scand J Clin Lab Invest 1993; 53(5):439-446.
- (35) Shimozuma K, Sonoo H, Fukunaga M, Ichihara K, Aoyama T, Tanaka K. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report. Jpn J Clin Oncol 1999; 29(1):16-22.
- (36) Chan DW, Beveridge RA, Muss H, Fritsche HA, Hortobagyi G, Theriault R et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 1997; 15(6):2322-2328.

- (37) Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G et al. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. *Br J Cancer* 1997; 75(5):698-702.
- (38) Zissimopoulos A, Petrakis G, Stellos K, Baziotis N. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer]. *Hell J Nucl Med* 2006; 9(1):60-64.
- (39) Begic A, Kucukalic-Selimovic E, Obralic N, Duric O, Lacevic N, Begovic S et al. Role of bone scintigraphy and tumor marker-Ca 15-3 in detection of bone metastases in patients with breast cancer. *Bosn J Basic Med Sci* 2005; 5(1):23-26.
- (40) Schoenberger J, Rozeboom S, Wirthgen-Beyer E, Eilles C. Evaluation of the clinical value of bone metabolic parameters for the screening of osseous metastases compared to bone scintigraphy. *BMC Nucl Med* 2004; 4(1):3.
- (41) Szulc P, Garnero P, Munoz F, Marchand F, Delmas PD. Cross-sectional evaluation of bone metabolism in men. *J Bone Miner Res* 2001; 16(9):1642-1650.
- (42) Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. *Osteoporos Int* 2000; 11(4):295-303.
- (43) Peris P, Alvarez L, Monegal A, Guanabens N, Duran M, Pons F et al. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. *Bone* 1999; 25(3):349-353.
- (44) Clinical Utility of Roche Diagnostics Serum Biochemical Markers of Bone Metabolism. 05 Apr; 2005.
- (45) Chen Z, Maricic M, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH et al. Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. *Cancer* 2005; 104(7):1520-1530.
- (46) Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. *Arch Intern Med* 2005; 165(5):552-558.
- (47) Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. *Br J Cancer* 1999; 79(7-8):1179-1181.
- (48) Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. *J Clin Oncol* 2003; 21(21):4042-4057.
- (49) Kobayashi Y, Ochi M, Tokue A. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP]. *Hinyokika Kyo* 2000; 46(12):869-872.

- (50) Kobayashi T, Gabazza EC, Taguchi O, Risteli J, Risteli L, Kobayashi H et al. Type I collagen metabolites as tumor markers in patients with lung carcinoma. *Cancer* 1999; 85(9):1951-1957.
- (51) Jensen BV, Johansen JS, Skovsgaard T, Brandt J, Teisner B. Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer. *Int J Cancer* 2002; 98(4):582-589.
- (52) Jukkola A, Tahtela R, Tholix E, Vuorinen K, Blanco G, Risteli L et al. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. *Cancer Res* 1997; 57(24):5517-5520.
- (53) Jukkola A, Bloigu R, Holli K, Joensuu H, Valavaara R, Risteli J et al. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer. *Anticancer Res* 2001; 21(4B):2873-2876.
- (54) Ingle BM, Hay SM, Bottjer HM, Eastell R. Changes in bone mass and bone turnover following ankle fracture. *Osteoporos Int* 1999; 10(5):408-415.
- (55) Ingle BM, Hay SM, Bottjer HM, Eastell R. Changes in bone mass and bone turnover following distal forearm fracture. *Osteoporos Int* 1999; 10(5):399-407.
- (56) Obrant KJ, Ivaska KK, Gerdhem P, Alatalo SL, Pettersson K, Vaananen HK. Biochemical markers of bone turnover are influenced by recently sustained fracture. *Bone* 2005; 36(5):786-792.
- (57) Body JJ, Dumon JC, Gineyts E, Delmas PD. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. *Br J Cancer* 1997; 75(3):408-412.
- (58) Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. *Br J Cancer* 2000; 82(4):858-864.
- (59) Koizumi M, Yonese J, Fukui I, Ogata E. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. *J Urol* 2002; 167(4):1863-1866.
- (60) Luftner D, Richter A, Geppert R, Wernecke KD, Possinger K. Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer. *Anticancer Res* 2003; 23(2A):1017-1026.
- (61) Kurebayashi J, Yamamoto Y, Tanaka K, Kohno N, Kurosumi M, Moriya T et al. Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study. *Breast Cancer* 2003; 10(1):38-44.
- (62) Kurebayashi J, Nishimura R, Tanaka K, Kohno N, Kurosumi M, Moriya T et al. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. *Breast Cancer* 2004; 11(4):389-395.

- (63) Robertson JF, Pearson D, Price MR, Selby C, Badley RA, Pearson J et al. Assessment of four monoclonal antibodies as serum markers in breast cancer. *Eur J Cancer* 1990; 26(11-12):1127-1132.
- (64) Robertson JF, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. *European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer* 1999; 35(1):47-53.
- (65) Sjostrom J, Alfthan H, Joensuu H, Stenman UH, Lundin J, Blomqvist C. Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer. *Scand J Clin Lab Invest* 2001; 61(6):431-441.
- (66) Van Dalen A, Barak V, Cremaschi A, Gion M, Molina R, Namer M et al. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. *Int J Biol Markers* 1998; 13(1):10-15.